- Details
- Description
-
Packaging Size30c/Bottle
-
Strength0.1mg
-
CompositonTalazoparib
-
TreatmentGermline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer;Metastatic castration-resistant prostate cancer (mCRPC)
-
FormCapsule
-
BrandLuciTala
-
Quantity Unit0.1mg*30c/Box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Talazoparib
Talazoparib is an orally available poly ADP ribose polymerase (PARP) inhibitor .Talazoparib is similar to the first in class PARP inhibitor, olaparib.
Breast Cancer
Indicated for adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer
1 mg PO qDay with or without food
Continue until disease progression or unacceptable toxicity occurs
Metastatic Castration-Resistant Prostate Cancer
Indicated in combination with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC)
0.5 mg PO qDay (in combination with enzalutamide)
Continue until disease progression or unacceptable toxicity
Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy